Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/12/24 | 8-K | Current report filing |
|
   |
2 |
| 09/09/24 | 8-K | Current report filing |
|
|
19 |
| 08/30/24 | 8-K | Current report filing |
|
|
2 |
| 08/19/24 | ARS | Annual report to security holders |
|
121 | |
| 08/19/24 | DEF 14A | Definitive proxy statements |
|
50 | |
| 08/19/24 | 8-K | Current report filing |
|
|
4 |
| 08/14/24 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
25 |
| 08/14/24 | 8-K | Current report filing |
|
|
5 |
| 08/09/24 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
51 | |
| 08/09/24 | 8-K | Current report filing |
|
|
2 |
